A proof-of-concept study, single-dose, cross-over, comparative bioavailability of AQS-1303 (transdermal doxylamine/pyridoxine long-acting patch), for the treatment of nausea and vomiting of pregnancy (NVP)

Trial Profile

A proof-of-concept study, single-dose, cross-over, comparative bioavailability of AQS-1303 (transdermal doxylamine/pyridoxine long-acting patch), for the treatment of nausea and vomiting of pregnancy (NVP)

Planning
Phase of Trial: Phase I

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Doxylamine/pyridoxine (Primary) ; Doxylamine/pyridoxine
  • Indications Nausea and vomiting
  • Focus Adverse reactions; Pharmacokinetics; Proof of concept
  • Sponsors Aequus Pharmaceuticals
  • Most Recent Events

    • 05 Jul 2017 According to an Aequus Pharmaceuticals media release, company has received approval from Health Canada to initiate this study.
    • 15 Jun 2017 According to an Aequus Pharmaceuticals media release, results are expected in Q3 2017
    • 15 Jun 2017 According to an Aequus Pharmaceuticals media release, the company has filed a Clinical Trial Application ("CTA") with Health Canada in preparation for this trial. The company plans to start this trial in early July after approval of the CTA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top